Combinatorial phenethyl isothiocyanate and withaferin A targets multiple epigenetics pathways to inhibit MCF-7 and

Mohammad Mijanur Rahman1, Trygve O Tollefsbol2,3,4,5,6

  • 1Department of Biology, University of Alabama at Birmingham, 3100 East Science Hall, 902 14th Street South, Birmingham, AL, 35294-1170, USA.

Cancer Cell International
|December 20, 2024
PubMed
Abstract

Insights

Combinatorial treatment with phenethyl isothiocyanate (PEITC) and withaferin A (WA) synergistically inhibits breast cancer cells by targeting multiple epigenetic pathways. This combination impacts cancer hallmarks and miRNome profiles, offering a promising epigenetic therapy approach.

Area of Science:

  • Epigenetics
  • Cancer Biology
  • Pharmacology

Background:

  • Epigenetic phytochemicals offer a safe alternative to synthetic drugs in cancer discovery.
  • Combinatorial interventions can target multiple neoplastic pathways simultaneously.
  • Phenethyl isothiocyanate (PEITC) and withaferin A (WA) are epigenetic-modifying compounds with potential in drug discovery.

Purpose of the Study:

  • To evaluate the effects of PEITC and WA, alone and in combination, on breast cancer (BC) cell hallmarks.
  • To analyze the impact of PEITC and WA on the miRNome profiles of BC cells.
  • To investigate the influence of PEITC and WA on multiple epigenetic regulatory pathways.

Main Methods:

  • MTT assay, cell cycle analysis, apoptosis assay, and stem cell assays were performed on MCF-7 and MDA-MB-231 BC cells.
  • HDAC and DNMT activity assays, western blot, siRNA-mediated gene knockdown, and RT-qPCR were used to assess epigenetic effects.
  • miRNA-seq and miRNA Real-Time PCR were employed to explore miRNome profile alterations.

Main Results:

  • Combined PEITC and WA synergistically inhibited BC cells, inducing G2/M-phase arrest and apoptosis while reducing tumor formation and stem cell populations.
  • The combination significantly reduced global DNA methyltransferase (DNMT) and histone deacetylase (HDAC) activity, along with decreasing expression of Class I HDACs and de novo DNMTs.
  • PEITC + WA treatment altered the expression of BC-associated miRNAs and mimicked the effects of HDAC8 and DNMT3B silencing on cell cycle and apoptosis-related proteins.

Conclusions:

  • Combined PEITC and WA effectively inhibit breast cancer cells by targeting multiple epigenetic regulatory pathways.
  • This combinatorial approach demonstrates potential as an epigenetic therapy for breast cancer.
  • The study highlights the impact of PEITC and WA on cancer hallmarks and miRNome profiles through epigenetic modulation.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K